NRX Pharmaceuticals
NRXP
6 hedge funds and large institutions have $345K invested in NRX Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
20% more funds holding
Funds holding: 5 → 6 (+1)
0.69% less ownership
Funds ownership: 0.74% → 0.05% (-0.69%)
84% less capital invested
Capital invested by funds: $2.16M → $345K (-$1.82M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$194K |
| 2 |
Morgan Stanley
New York
|
+$22.3K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$8.21K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$1.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$1.25M |
| 2 |
GCL
Glazer Capital LLC
New York
|
-$718K |
| 3 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$176K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.78K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
1
HRT Financial
New York
| $288K | +$194K | +1,181 | New |
|
|
2
Morgan Stanley
New York
| $33K | +$22.3K | +136 | New |
|
|
3
Osaic Holdings
Scottsdale,
Arizona
| $12K | +$8.21K | +50 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $6K | -$3.78K | -23 | -50% |
|
5
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $4K | – | – | – |
|
|
WAM
6
Wolverine Asset Management
Chicago,
Illinois
| $2K | +$1.64K | +10 | New |
|
|
MF
7
Magnetar Financial
Evanston,
Illinois
| – | -$1.25M | -11,600 | Closed |
|
|
GCL
8
Glazer Capital LLC
New York
| – | -$718K | -6,698 | Closed |
|
|
YCM
9
Yakira Capital Management
Westport,
Connecticut
| – | -$176K | -1,641 | Closed |
|
NRXP Hedge Fund Activity: Q4 2020 in Review
6 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q4 2020, worth a combined $345K — down 84% from $2.16M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NRXP positions and 3 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $194K. The largest seller was Magnetar Financial, exiting entirely with an estimated $1.25M sold.
- 6 institutional investors held NRX Pharmaceuticals (NRXP) as of Q4 2020, up from 5 in Q3 2020.
- Funds reported $345K of NRX Pharmaceuticals stock for Q4 2020, down 84% quarter-over-quarter.
- 4 funds opened new NRX Pharmaceuticals positions in Q4 2020 and 3 closed out, a net change of +1 holder.
- The largest NRX Pharmaceuticals buyer in Q4 2020 was HRT Financial, an estimated $194K added.
- The largest NRX Pharmaceuticals seller in Q4 2020 was Magnetar Financial, an estimated $1.25M sold.
Based on aggregated 13F filings for Q4 2020.